230 related articles for article (PubMed ID: 35501287)
1. Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India.
Ranjan MK; Kante B; Vuyyuru SK; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
J Gastroenterol Hepatol; 2022 Aug; 37(8):1544-1553. PubMed ID: 35501287
[TBL] [Abstract][Full Text] [Related]
2. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
Stournaras E; Qian W; Pappas A; Hong YY; Shawky R; ; Raine T; Parkes M;
Gut; 2021 Apr; 70(4):677-686. PubMed ID: 33004550
[TBL] [Abstract][Full Text] [Related]
3. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
4. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
[TBL] [Abstract][Full Text] [Related]
5. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
Ranjan MK; Vuyyuru SK; Kante B; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
Int J Colorectal Dis; 2022 Aug; 37(8):1817-1826. PubMed ID: 35835862
[TBL] [Abstract][Full Text] [Related]
6. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
7. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study.
Setshedi M; Epstein D; Winter TA; Myer L; Watermeyer G; Hift R
J Gastroenterol Hepatol; 2012 Feb; 27(2):385-9. PubMed ID: 21793904
[TBL] [Abstract][Full Text] [Related]
8. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
[TBL] [Abstract][Full Text] [Related]
9. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients.
Kennedy NA; Kalla R; Warner B; Gambles CJ; Musy R; Reynolds S; Dattani R; Nayee H; Felwick R; Harris R; Marriott S; Senanayake SM; Lamb CA; Al-Hilou H; Gaya DR; Irving PM; Mansfield J; Parkes M; Ahmad T; Cummings JR; Arnott ID; Satsangi J; Lobo AJ; Smith M; Lindsay JO; Lees CW
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1313-23. PubMed ID: 25284134
[TBL] [Abstract][Full Text] [Related]
10. Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis.
Ranjan MK; Kumar P; Vuyyuru SK; Kante B; Mundhra SK; Golla R; Virmani S; Sharma R; Sahni P; Das P; Kalaivani M; Upadhyay AD; Makharia G; Kedia S; Ahuja V
J Crohns Colitis; 2024 Feb; 18(2):192-203. PubMed ID: 37584328
[TBL] [Abstract][Full Text] [Related]
11. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.
Bermejo F; Aguas M; Chaparro M; Domènech E; Echarri A; García-Planella E; Guerra I; Gisbert JP; López-Sanromán A;
Gastroenterol Hepatol; 2018 Mar; 41(3):205-221. PubMed ID: 29357999
[TBL] [Abstract][Full Text] [Related]
12. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study.
Jagt JZ; Pothof CD; Buiter HJC; van Limbergen JE; van Wijk MP; Benninga MA; de Boer NKH; de Meij TGJ
Dig Dis Sci; 2022 Jan; 67(1):241-251. PubMed ID: 33532972
[TBL] [Abstract][Full Text] [Related]
13. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
Kobayashi T; Uda A; Udagawa E; Hibi T
J Crohns Colitis; 2020 Jun; 14(5):617-623. PubMed ID: 31867632
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.
Barber GE; Hendler S; Choe M; Keyashian K; Lechner S; Limketkai BN; Limsui D
Dig Dis Sci; 2022 Apr; 67(4):1287-1294. PubMed ID: 33755823
[TBL] [Abstract][Full Text] [Related]
15. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.
Kakuta Y; Naito T; Onodera M; Kuroha M; Kimura T; Shiga H; Endo K; Negoro K; Kinouchi Y; Shimosegawa T
Pharmacogenomics J; 2016 Jun; 16(3):280-5. PubMed ID: 26076924
[TBL] [Abstract][Full Text] [Related]
16. Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease.
Rezazadeh Ardabili A; Jeuring S; Mujagic Z; Oostenbrug L; Romberg-Camps M; Jonkers D; van Bodegraven A; Pierik M
Aliment Pharmacol Ther; 2022 Sep; 56(6):1030-1043. PubMed ID: 35794735
[TBL] [Abstract][Full Text] [Related]
17. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis.
Kennedy NA; Rhatigan E; Arnott ID; Noble CL; Shand AG; Satsangi J; Lees CW
Aliment Pharmacol Ther; 2013 Nov; 38(10):1255-66. PubMed ID: 24117596
[TBL] [Abstract][Full Text] [Related]
18. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
19. Uphill battle: Innovation of thiopurine therapy in global inflammatory bowel disease care.
Bayoumy AB; Mulder CJJ; Ansari AR; Barclay ML; Florin T; Kiszka-Kanowitz M; Derijks L; Sharma V; de Boer NKH
Indian J Gastroenterol; 2024 Feb; 43(1):36-47. PubMed ID: 38383877
[TBL] [Abstract][Full Text] [Related]
20. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
Chaparro M; Ordás I; Cabré E; Garcia-Sanchez V; Bastida G; Peñalva M; Gomollón F; García-Planella E; Merino O; Gutiérrez A; Esteve M; Márquez L; Garcia-Sepulcre M; Hinojosa J; Vera I; Muñoz F; Mendoza JL; Cabriada JL; Montoro MA; Barreiro-de Acosta M; Ceña G; Saro C; Aldeguer X; Barrio J; Maté J; Gisbert JP
Inflamm Bowel Dis; 2013 Jun; 19(7):1404-10. PubMed ID: 23665964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
